The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a ...
Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
The drug, fosdenopterin, is a treatment for molybdenum cofactor deficiency (MoCD) type A. Babies born with this disease experience a rapid progression of neurological problems including seizures, ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN), today announced that the U.S. Food and Drug Administration (FDA) ...
PALO ALTO, Calif. and SOLANA BEACH, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic ...
SAN FRANCISCO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Origin Biosciences today announced the US Food and Drug Administration (FDA) has accepted its New ...
Without treatment, MoCD type A results in severe impairments such as seizures and severe developmental and movement disorders, and often leads to early death within the first few months of life. Until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results